organization · Reporting owner

JPMP GLOBAL INVESTORS L P

Disclosed activity across 5 companies

Tapewire entity: 13661
SEC CIK: 0001281161

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ANESIVA, INC.ANSV · Entity 13652	10% owner	June 22, 2006	June 26, 2006
BARRIER THERAPEUTICS INCBTRX · Entity 13927	10% owner	December 30, 2004	January 04, 2005
PortalPlayer, Inc.PLAY · Entity 13955	10% owner	December 31, 2004	January 04, 2005
Seagen Inc.SGEN · Entity 13956	10% owner	December 30, 2004	January 04, 2005

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ANESIVA, INC.

Report date June 22, 2006 · Filed June 26, 2006

Jointly reported with J P MORGAN PARTNERS SBIC LLC, JP MORGAN PARTNERS BHCA LP, JPMP MASTER FUND MANAGER L P, JPMP CAPITAL LLC, JPMORGAN CHASE & CO, JP MORGAN PARTNERS GLOBAL INVESTORS LP, J P MORGAN PARTNERS GLOBAL INVESTORS A LP, J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN LP, J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN II LP

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.87 · Expires 2016-06-22	IndirectSee footnote	10,000	Reported balance After 2006-06-22 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2006-06-22 · Grant · Acquired 10,000 · Balance 10,000 F9: These options were granted to Rodney A. Ferguson, a director of the Issuer. Mr. Ferguson is obligated to transfer any shares issued under the option to JPM SBIC. The option is immediately exercisable. Shares subject to the option vest monthly over 12 months. The Reporting Person has no pecuniary interest in such securities.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.20 · Expires 2012-12-03	IndirectSee footnote	10,000	Reported balance Holding disclosure · report date 2006-06-22 · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · Balance 10,000 F6: These options were granted to Rodney A. Ferguson, a director of the Issuer. Mr. Ferguson is a Managing Director of J.P. Morgan Partners (SBIC), LLC ("JPM SBIC"). Mr. Ferguson is obligated to transfer any shares issued under the option to JPM SBIC. The option is immediately exercisable. Shares subject to the option vest monthly over 48 months. The Reporting Person has no pecuniary interest in such securities.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.44 · Expires 2015-06-07	IndirectSee footnote	2,500	Reported balance Holding disclosure · report date 2006-06-22 · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · Balance 2,500 F7: These options were granted to Rodney A. Ferguson, a director of the Issuer. Mr. Ferguson is obligated to transfer any shares issued under the option to JPM SBIC. The option is immediately exercisable. Shares subject to the option vest monthly over 12 months. The Reporting Person has no pecuniary interest in such securities.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.80 · Expires 2015-12-16	IndirectSee footnote	50,000	Reported balance Holding disclosure · report date 2006-06-22 · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · Balance 50,000 F8: These options were granted to Rodney A. Ferguson, a director of the Issuer. Mr. Ferguson is obligated to transfer any shares issued under the option to JPM SBIC. The option is immediately exercisable. One-quarter of these shares are immediately vested, the remainder of the shares will vest in equal monthly installments over 48 months. The Reporting Person has no pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	Direct	2,886,121	Reported balance Holding disclosure · report date 2006-06-22 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 2,886,121
Common StockSEC Table I · non-derivative	IndirectSee footnote	234,689	Reported balance Holding disclosure · report date 2006-06-22 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 234,689 F1: The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors, L.P. The Reporting Person has no pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	35,134	Reported balance Holding disclosure · report date 2006-06-22 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 35,134 F2: The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors A, L.P. The Reporting Person has no pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	118,118	Reported balance Holding disclosure · report date 2006-06-22 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 118,118 F3: The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors (Cayman), L.P. The Reporting Person has no pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	13,198	Reported balance Holding disclosure · report date 2006-06-22 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 13,198 F4: The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors (Cayman II), L.P. The Reporting Person has no pecuniary interest n such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	81,769	Reported balance Holding disclosure · report date 2006-06-22 · row 6 Holding and transaction disclosures are not merged. 1 source row Row 6 · Balance 81,769 F5: The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors (Selldown), L.P. The Reporting Person has no pecuniary interest in such securities.

Filing footnotes · ownership attribution and instrument terms

F1: The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors, L.P. The Reporting Person has no pecuniary interest in such securities.

F2: The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors A, L.P. The Reporting Person has no pecuniary interest in such securities.

F3: The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors (Cayman), L.P. The Reporting Person has no pecuniary interest in such securities.

F4: The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors (Cayman II), L.P. The Reporting Person has no pecuniary interest n such securities.

F5: The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors (Selldown), L.P. The Reporting Person has no pecuniary interest in such securities.

F6: These options were granted to Rodney A. Ferguson, a director of the Issuer. Mr. Ferguson is a Managing Director of J.P. Morgan Partners (SBIC), LLC ("JPM SBIC"). Mr. Ferguson is obligated to transfer any shares issued under the option to JPM SBIC. The option is immediately exercisable. Shares subject to the option vest monthly over 48 months. The Reporting Person has no pecuniary interest in such securities.

F7: These options were granted to Rodney A. Ferguson, a director of the Issuer. Mr. Ferguson is obligated to transfer any shares issued under the option to JPM SBIC. The option is immediately exercisable. Shares subject to the option vest monthly over 12 months. The Reporting Person has no pecuniary interest in such securities.

F8: These options were granted to Rodney A. Ferguson, a director of the Issuer. Mr. Ferguson is obligated to transfer any shares issued under the option to JPM SBIC. The option is immediately exercisable. One-quarter of these shares are immediately vested, the remainder of the shares will vest in equal monthly installments over 48 months. The Reporting Person has no pecuniary interest in such securities.

F9: These options were granted to Rodney A. Ferguson, a director of the Issuer. Mr. Ferguson is obligated to transfer any shares issued under the option to JPM SBIC. The option is immediately exercisable. Shares subject to the option vest monthly over 12 months. The Reporting Person has no pecuniary interest in such securities.

BARRIER THERAPEUTICS INC

Report date December 30, 2004 · Filed January 04, 2005

Jointly reported with JP MORGAN PARTNERS BHCA LP, JPMP MASTER FUND MANAGER L P, JPMP CAPITAL LLC, JPMORGAN CHASE & CO, JP MORGAN PARTNERS GLOBAL INVESTORS LP, J P MORGAN PARTNERS GLOBAL INVESTORS A LP, J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN LP, J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN II LP

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,323,666	Reported balance After 2004-12-30 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2004-12-30 · Sale · Disposed 147,134 · Balance 2,323,666
Common StockSEC Table I · non-derivative	IndirectSee footnote	147,134	Reported balance After 2004-12-30 transaction · row 6 Holding and transaction disclosures are not merged. 1 source row Row 6 · 2004-12-30 · Purchase · Acquired 147,134 · Balance 147,134 F5: The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors (Selldown), L.P. ("Selldown").
Common StockSEC Table I · non-derivative	IndirectSee footnote	397,975	Reported balance Holding disclosure · report date 2004-12-30 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 397,975 F1: The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors, L.P.
Common StockSEC Table I · non-derivative	IndirectSee footnote	201,635	Reported balance Holding disclosure · report date 2004-12-30 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 201,635 F2: The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors (Cayman), L.P.
Common StockSEC Table I · non-derivative	IndirectSee footnote	55,380	Reported balance Holding disclosure · report date 2004-12-30 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 55,380 F3: The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors A, L.P.
Common StockSEC Table I · non-derivative	IndirectSee footnote	22,483	Reported balance Holding disclosure · report date 2004-12-30 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 22,483 F4: The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors (Cayman) II, L.P.

Filing footnotes · ownership attribution and instrument terms

F1: The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors, L.P.

F2: The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors (Cayman), L.P.

F3: The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors A, L.P.

F4: The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors (Cayman) II, L.P.

F5: The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors (Selldown), L.P. ("Selldown").

PortalPlayer, Inc.

Report date December 31, 2004 · Filed January 04, 2005

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,560,225	Reported balance After 2004-12-31 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2004-12-31 · Sale · Disposed 86,322 · Balance 2,560,225
Common StockSEC Table I · non-derivative	IndirectSee footnote	86,322	Reported balance After 2004-12-31 transaction · row 6 Holding and transaction disclosures are not merged. 1 source row Row 6 · 2004-12-31 · Purchase · Acquired 86,322 · Balance 86,322 F5: The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors (Selldown), L.P.
Common StockSEC Table I · non-derivative	IndirectSee footnote	229,704	Reported balance Holding disclosure · report date 2004-12-31 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 229,704 F1: The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors, L.P.
Common StockSEC Table I · non-derivative	IndirectSee footnote	31,313	Reported balance Holding disclosure · report date 2004-12-31 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 31,313 F2: The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors A, L.P.
Common StockSEC Table I · non-derivative	IndirectSee footnote	116,587	Reported balance Holding disclosure · report date 2004-12-31 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 116,587 F3: The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors (Cayman), L.P. ("Cayman").
Common StockSEC Table I · non-derivative	IndirectSee footnote	12,992	Reported balance Holding disclosure · report date 2004-12-31 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 12,992 F4: The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors (Cayman) II, L.P. ("Cayman II").

Filing footnotes · ownership attribution and instrument terms

F1: The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors, L.P.

F2: The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors A, L.P.

F3: The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors (Cayman), L.P. ("Cayman").

F4: The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors (Cayman) II, L.P. ("Cayman II").

F5: The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors (Selldown), L.P.

Seagen Inc.

Report date December 30, 2004 · Filed January 04, 2005

Security / award	Ownership account	Disclosed shares / units	Disclosure context
WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $6.25 · Expires 2011-12-31	Direct	601,925	Reported balance After 2004-12-30 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2004-12-30 · Sale · Disposed 38,114 · Balance 601,925
WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $6.25 · Expires 2011-12-31	IndirectSee footnote	381,140	Reported balance After 2004-12-30 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2004-12-30 · Purchase · Acquired 38,114 · Balance 381,140 F5: The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors (Selldown), L.P.
WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $6.25 · Expires 2011-12-31	IndirectSee footnote	101,421	Reported balance Holding disclosure · report date 2004-12-30 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance 101,421 F1: The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors, L.P.
WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $6.25 · Expires 2011-12-31	IndirectSee footnote	13,826	Reported balance Holding disclosure · report date 2004-12-30 · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · Balance 13,826 F2: The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors (Cayman), L.P.
WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $6.25 · Expires 2011-12-31	IndirectSee footnote	51,478	Reported balance Holding disclosure · report date 2004-12-30 · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · Balance 51,478 F3: The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors A, L.P.
WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $6.25 · Expires 2011-12-31	IndirectSee footnote	5,736	Reported balance Holding disclosure · report date 2004-12-30 · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · Balance 5,736 F4: The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors (Cayman) II, L.P.
Series A Convertible Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $2.50	Direct	4,815,400	Reported balance After 2004-12-30 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2004-12-30 · Sale · Disposed 30,491 · Balance 4,815,400 F6: The conversion price of the Series A Convertible Preferred Stock is equal to the initial purchase price divided by $2.50, as adjusted for stock splits, stock dividends, combinations and other similar capitalizations of the Issuer's Common and Preferred Stock. Initially this results in a 1 for 10 conversion ratio. Each share of Series A Convertible Preferred Stock is entitled to 0.93 votes for each share of Common Stock into which such share of Convertible Preferred Stock could then be converted. F7: All outstanding shares of the Issuer's Series A Convertible Preferred Stock are convertible at the holder's option into shares of the Issuer's Common Stock on a 10 to 1 basis any time after July 8, 2004. This right to convert does not expire.
Series A Convertible Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $2.50	IndirectSee footnote	304,910	Reported balance After 2004-12-30 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2004-12-30 · Purchase · Acquired 30,491 · Balance 304,910 F6: The conversion price of the Series A Convertible Preferred Stock is equal to the initial purchase price divided by $2.50, as adjusted for stock splits, stock dividends, combinations and other similar capitalizations of the Issuer's Common and Preferred Stock. Initially this results in a 1 for 10 conversion ratio. Each share of Series A Convertible Preferred Stock is entitled to 0.93 votes for each share of Common Stock into which such share of Convertible Preferred Stock could then be converted. F7: All outstanding shares of the Issuer's Series A Convertible Preferred Stock are convertible at the holder's option into shares of the Issuer's Common Stock on a 10 to 1 basis any time after July 8, 2004. This right to convert does not expire. F5: The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors (Selldown), L.P.
Series A Convertible Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $2.50	IndirectSee footnote	811,370	Reported balance Holding disclosure · report date 2004-12-30 · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · Balance 811,370 F6: The conversion price of the Series A Convertible Preferred Stock is equal to the initial purchase price divided by $2.50, as adjusted for stock splits, stock dividends, combinations and other similar capitalizations of the Issuer's Common and Preferred Stock. Initially this results in a 1 for 10 conversion ratio. Each share of Series A Convertible Preferred Stock is entitled to 0.93 votes for each share of Common Stock into which such share of Convertible Preferred Stock could then be converted. F7: All outstanding shares of the Issuer's Series A Convertible Preferred Stock are convertible at the holder's option into shares of the Issuer's Common Stock on a 10 to 1 basis any time after July 8, 2004. This right to convert does not expire. F1: The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors, L.P.
Series A Convertible Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $2.50	IndirectSee footnote	110,610	Reported balance Holding disclosure · report date 2004-12-30 · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · Balance 110,610 F6: The conversion price of the Series A Convertible Preferred Stock is equal to the initial purchase price divided by $2.50, as adjusted for stock splits, stock dividends, combinations and other similar capitalizations of the Issuer's Common and Preferred Stock. Initially this results in a 1 for 10 conversion ratio. Each share of Series A Convertible Preferred Stock is entitled to 0.93 votes for each share of Common Stock into which such share of Convertible Preferred Stock could then be converted. F7: All outstanding shares of the Issuer's Series A Convertible Preferred Stock are convertible at the holder's option into shares of the Issuer's Common Stock on a 10 to 1 basis any time after July 8, 2004. This right to convert does not expire. F2: The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors (Cayman), L.P.
Series A Convertible Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $2.50	IndirectSee footnote	411,820	Reported balance Holding disclosure · report date 2004-12-30 · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · Balance 411,820 F6: The conversion price of the Series A Convertible Preferred Stock is equal to the initial purchase price divided by $2.50, as adjusted for stock splits, stock dividends, combinations and other similar capitalizations of the Issuer's Common and Preferred Stock. Initially this results in a 1 for 10 conversion ratio. Each share of Series A Convertible Preferred Stock is entitled to 0.93 votes for each share of Common Stock into which such share of Convertible Preferred Stock could then be converted. F7: All outstanding shares of the Issuer's Series A Convertible Preferred Stock are convertible at the holder's option into shares of the Issuer's Common Stock on a 10 to 1 basis any time after July 8, 2004. This right to convert does not expire. F3: The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors A, L.P.
Series A Convertible Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $2.50	IndirectSee footnote	45,890	Reported balance Holding disclosure · report date 2004-12-30 · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · Balance 45,890 F6: The conversion price of the Series A Convertible Preferred Stock is equal to the initial purchase price divided by $2.50, as adjusted for stock splits, stock dividends, combinations and other similar capitalizations of the Issuer's Common and Preferred Stock. Initially this results in a 1 for 10 conversion ratio. Each share of Series A Convertible Preferred Stock is entitled to 0.93 votes for each share of Common Stock into which such share of Convertible Preferred Stock could then be converted. F7: All outstanding shares of the Issuer's Series A Convertible Preferred Stock are convertible at the holder's option into shares of the Issuer's Common Stock on a 10 to 1 basis any time after July 8, 2004. This right to convert does not expire. F4: The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors (Cayman) II, L.P.
Stock Options (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $7.26 · Expires 2014-05-16	IndirectSee footnote	10,000	Reported balance Holding disclosure · report date 2004-12-30 · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · Balance 10,000 F8: These options were granted to Srinivas Akkaraju, a director of the Issuer. Mr. Akkaraju is obligated to transfer any shares issued under the Stock Option to J.P. Morgan Partners (BHCA), L.P. ("JPM BHCA") at the request of JPM BHCA.

Filing footnotes · ownership attribution and instrument terms

F1: The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors, L.P.

F2: The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors (Cayman), L.P.

F3: The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors A, L.P.

F4: The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors (Cayman) II, L.P.

F5: The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors (Selldown), L.P.

F6: The conversion price of the Series A Convertible Preferred Stock is equal to the initial purchase price divided by $2.50, as adjusted for stock splits, stock dividends, combinations and other similar capitalizations of the Issuer's Common and Preferred Stock. Initially this results in a 1 for 10 conversion ratio. Each share of Series A Convertible Preferred Stock is entitled to 0.93 votes for each share of Common Stock into which such share of Convertible Preferred Stock could then be converted.

F7: All outstanding shares of the Issuer's Series A Convertible Preferred Stock are convertible at the holder's option into shares of the Issuer's Common Stock on a 10 to 1 basis any time after July 8, 2004. This right to convert does not expire.

F8: These options were granted to Srinivas Akkaraju, a director of the Issuer. Mr. Akkaraju is obligated to transfer any shares issued under the Stock Option to J.P. Morgan Partners (BHCA), L.P. ("JPM BHCA") at the request of JPM BHCA.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

NUCO2 INC /FL

Report date December 15, 2004 · Filed December 17, 2004

Section 16 reporting ended · disclosed 2004-12-17. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,029,178	Reported balance After 2004-12-15 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2004-12-15 · Sale · Disposed 344,730 · Balance 1,029,178
Common StockSEC Table I · non-derivative	IndirectSee footnote	16,135	Reported balance After 2004-12-15 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2004-12-15 · Sale · Disposed 5,092 · Balance 16,135 F1: The amounts shown represent the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors, L.P.
Common StockSEC Table I · non-derivative	IndirectSee footnote	8,101	Reported balance After 2004-12-15 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2004-12-15 · Sale · Disposed 2,556 · Balance 8,101 F2: The amounts shown represent the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors (Cayman), L.P.
Common StockSEC Table I · non-derivative	IndirectSee footnote	2,479	Reported balance After 2004-12-15 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2004-12-15 · Sale · Disposed 782 · Balance 2,479 F3: The amounts shown represent the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors A, L.P.
Common StockSEC Table I · non-derivative	IndirectSee footnote	905	Reported balance After 2004-12-15 transaction · row 5 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 5 · 2004-12-15 · Sale · Disposed 285 · Balance 905 F4: The amounts shown represent the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors (Cayman) II, L.P.
Options (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $7.82 · Expires 2011-01-01	IndirectSee footnote	2,000	Reported balance Holding disclosure · report date 2004-12-15 · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · Balance 2,000 F5: These options are immediately exercisable. F6: The option was granted to Richard Waters, a limited partner of the JPMP Master Fund Manager, L.P., which is the general partner of J.P. Morgan Partners (BHCA), L.P. ("JPM BHCA") and a Managing Director of the general partner of JPMP Master Fund Manager, L.P. Mr. Waters is obligated to exercise the option at the request of, and to transfer any shares issued under the stock option to, JPM BHCA. All shares issued under the stock option were transferred to JPM BHCA. Mr. Waters ceased to be a director of the Issuer on December 10, 2004.
Options (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $4.85 · Expires 2013-03-12	IndirectSee footnote	2,000	Reported balance Holding disclosure · report date 2004-12-15 · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · Balance 2,000 F5: These options are immediately exercisable. F6: The option was granted to Richard Waters, a limited partner of the JPMP Master Fund Manager, L.P., which is the general partner of J.P. Morgan Partners (BHCA), L.P. ("JPM BHCA") and a Managing Director of the general partner of JPMP Master Fund Manager, L.P. Mr. Waters is obligated to exercise the option at the request of, and to transfer any shares issued under the stock option to, JPM BHCA. All shares issued under the stock option were transferred to JPM BHCA. Mr. Waters ceased to be a director of the Issuer on December 10, 2004.

Filing footnotes · ownership attribution and instrument terms

F1: The amounts shown represent the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors, L.P.

F2: The amounts shown represent the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors (Cayman), L.P.

F3: The amounts shown represent the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors A, L.P.

F4: The amounts shown represent the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors (Cayman) II, L.P.

F5: These options are immediately exercisable.

F6: The option was granted to Richard Waters, a limited partner of the JPMP Master Fund Manager, L.P., which is the general partner of J.P. Morgan Partners (BHCA), L.P. ("JPM BHCA") and a Managing Director of the general partner of JPMP Master Fund Manager, L.P. Mr. Waters is obligated to exercise the option at the request of, and to transfer any shares issued under the stock option to, JPM BHCA. All shares issued under the stock option were transferred to JPM BHCA. Mr. Waters ceased to be a director of the Issuer on December 10, 2004.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
April 28, 2004 Filed Apr 30, 2004 18:52 UTC	BARRIER THERAPEUTICS INC BTRX · Entity 13927	ConversionSeries C Convertible Preferred Stock · Derivative	65,370	$0.00	$0.00	Disclosure SEC source: 0001125282-04-001878 · b331679_ex.xml · derivative · entry 13 JP MORGAN PARTNERS BHCA LP · CIK 0001106607 · 10% owner JPMP MASTER FUND MANAGER L P · CIK 0001243235 · 10% owner JPMP CAPITAL CORP · CIK 0001243236 · 10% owner J P MORGAN CHASE & CO · CIK 0000019617 · 10% owner JP MORGAN PARTNERS GLOBAL INVESTORS LP · CIK 0001162622 · 10% owner J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN LP · CIK 0001169890 · 10% owner J P MORGAN PARTNERS GLOBAL INVESTORS A LP · CIK 0001167095 · 10% owner J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN II LP · CIK 0001169889 · 10% owner JPMP GLOBAL INVESTORS L P · CIK 0001281161 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 32,685 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: The Series B and Series C Convertible Preferred Stock is immediately exercisable. It has no expiration date. Upon the close of the Issuer's initial public offering, these shares were automatically converted into Common Stock of the Issuer. These shares are convertible on a two for one basis. F5 · derivative.expiration_date: The Series B and Series C Convertible Preferred Stock is immediately exercisable. It has no expiration date. Upon the close of the Issuer's initial public offering, these shares were automatically converted into Common Stock of the Issuer. These shares are convertible on a two for one basis. F2 · ownership.nature: The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors (Cayman), L.P. Read SEC document
April 28, 2004 Filed Apr 30, 2004 18:52 UTC	BARRIER THERAPEUTICS INC BTRX · Entity 13927	ConversionSeries C Convertible Preferred Stock · Derivative	130,207	$0.00	$0.00	Disclosure SEC source: 0001125282-04-001878 · b331679_ex.xml · derivative · entry 12 JP MORGAN PARTNERS BHCA LP · CIK 0001106607 · 10% owner JPMP MASTER FUND MANAGER L P · CIK 0001243235 · 10% owner JPMP CAPITAL CORP · CIK 0001243236 · 10% owner J P MORGAN CHASE & CO · CIK 0000019617 · 10% owner JP MORGAN PARTNERS GLOBAL INVESTORS LP · CIK 0001162622 · 10% owner J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN LP · CIK 0001169890 · 10% owner J P MORGAN PARTNERS GLOBAL INVESTORS A LP · CIK 0001167095 · 10% owner J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN II LP · CIK 0001169889 · 10% owner JPMP GLOBAL INVESTORS L P · CIK 0001281161 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 65,103 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: The Series B and Series C Convertible Preferred Stock is immediately exercisable. It has no expiration date. Upon the close of the Issuer's initial public offering, these shares were automatically converted into Common Stock of the Issuer. These shares are convertible on a two for one basis. F5 · derivative.expiration_date: The Series B and Series C Convertible Preferred Stock is immediately exercisable. It has no expiration date. Upon the close of the Issuer's initial public offering, these shares were automatically converted into Common Stock of the Issuer. These shares are convertible on a two for one basis. F1 · ownership.nature: The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors, L.P. Read SEC document
April 28, 2004 Filed Apr 30, 2004 18:52 UTC	BARRIER THERAPEUTICS INC BTRX · Entity 13927	ConversionSeries C Convertible Preferred Stock · Derivative	740,321	$0.00	$0.00	Disclosure SEC source: 0001125282-04-001878 · b331679_ex.xml · derivative · entry 11 JP MORGAN PARTNERS BHCA LP · CIK 0001106607 · 10% owner JPMP MASTER FUND MANAGER L P · CIK 0001243235 · 10% owner JPMP CAPITAL CORP · CIK 0001243236 · 10% owner J P MORGAN CHASE & CO · CIK 0000019617 · 10% owner JP MORGAN PARTNERS GLOBAL INVESTORS LP · CIK 0001162622 · 10% owner J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN LP · CIK 0001169890 · 10% owner J P MORGAN PARTNERS GLOBAL INVESTORS A LP · CIK 0001167095 · 10% owner J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN II LP · CIK 0001169889 · 10% owner JPMP GLOBAL INVESTORS L P · CIK 0001281161 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 370,160 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: The Series B and Series C Convertible Preferred Stock is immediately exercisable. It has no expiration date. Upon the close of the Issuer's initial public offering, these shares were automatically converted into Common Stock of the Issuer. These shares are convertible on a two for one basis. F5 · derivative.expiration_date: The Series B and Series C Convertible Preferred Stock is immediately exercisable. It has no expiration date. Upon the close of the Issuer's initial public offering, these shares were automatically converted into Common Stock of the Issuer. These shares are convertible on a two for one basis. Read SEC document
April 28, 2004 Filed Apr 30, 2004 18:52 UTC	BARRIER THERAPEUTICS INC BTRX · Entity 13927	ConversionSeries B Convertible Preferred Stock · Derivative	37,657	$0.00	$0.00	Disclosure SEC source: 0001125282-04-001878 · b331679_ex.xml · derivative · entry 10 JP MORGAN PARTNERS BHCA LP · CIK 0001106607 · 10% owner JPMP MASTER FUND MANAGER L P · CIK 0001243235 · 10% owner JPMP CAPITAL CORP · CIK 0001243236 · 10% owner J P MORGAN CHASE & CO · CIK 0000019617 · 10% owner JP MORGAN PARTNERS GLOBAL INVESTORS LP · CIK 0001162622 · 10% owner J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN LP · CIK 0001169890 · 10% owner J P MORGAN PARTNERS GLOBAL INVESTORS A LP · CIK 0001167095 · 10% owner J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN II LP · CIK 0001169889 · 10% owner JPMP GLOBAL INVESTORS L P · CIK 0001281161 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 18,828 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: The Series B and Series C Convertible Preferred Stock is immediately exercisable. It has no expiration date. Upon the close of the Issuer's initial public offering, these shares were automatically converted into Common Stock of the Issuer. These shares are convertible on a two for one basis. F5 · derivative.expiration_date: The Series B and Series C Convertible Preferred Stock is immediately exercisable. It has no expiration date. Upon the close of the Issuer's initial public offering, these shares were automatically converted into Common Stock of the Issuer. These shares are convertible on a two for one basis. F4 · ownership.nature: The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors (Cayman) II, L.P. Read SEC document
April 28, 2004 Filed Apr 30, 2004 18:52 UTC	BARRIER THERAPEUTICS INC BTRX · Entity 13927	ConversionSeries B Convertible Preferred Stock · Derivative	90,754	$0.00	$0.00	Disclosure SEC source: 0001125282-04-001878 · b331679_ex.xml · derivative · entry 9 JP MORGAN PARTNERS BHCA LP · CIK 0001106607 · 10% owner JPMP MASTER FUND MANAGER L P · CIK 0001243235 · 10% owner JPMP CAPITAL CORP · CIK 0001243236 · 10% owner J P MORGAN CHASE & CO · CIK 0000019617 · 10% owner JP MORGAN PARTNERS GLOBAL INVESTORS LP · CIK 0001162622 · 10% owner J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN LP · CIK 0001169890 · 10% owner J P MORGAN PARTNERS GLOBAL INVESTORS A LP · CIK 0001167095 · 10% owner J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN II LP · CIK 0001169889 · 10% owner JPMP GLOBAL INVESTORS L P · CIK 0001281161 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 45,377 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: The Series B and Series C Convertible Preferred Stock is immediately exercisable. It has no expiration date. Upon the close of the Issuer's initial public offering, these shares were automatically converted into Common Stock of the Issuer. These shares are convertible on a two for one basis. F5 · derivative.expiration_date: The Series B and Series C Convertible Preferred Stock is immediately exercisable. It has no expiration date. Upon the close of the Issuer's initial public offering, these shares were automatically converted into Common Stock of the Issuer. These shares are convertible on a two for one basis. F3 · ownership.nature: The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors A, L.P. Read SEC document
April 28, 2004 Filed Apr 30, 2004 18:52 UTC	BARRIER THERAPEUTICS INC BTRX · Entity 13927	ConversionSeries B Convertible Preferred Stock · Derivative	337,900	$0.00	$0.00	Disclosure SEC source: 0001125282-04-001878 · b331679_ex.xml · derivative · entry 8 JP MORGAN PARTNERS BHCA LP · CIK 0001106607 · 10% owner JPMP MASTER FUND MANAGER L P · CIK 0001243235 · 10% owner JPMP CAPITAL CORP · CIK 0001243236 · 10% owner J P MORGAN CHASE & CO · CIK 0000019617 · 10% owner JP MORGAN PARTNERS GLOBAL INVESTORS LP · CIK 0001162622 · 10% owner J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN LP · CIK 0001169890 · 10% owner J P MORGAN PARTNERS GLOBAL INVESTORS A LP · CIK 0001167095 · 10% owner J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN II LP · CIK 0001169889 · 10% owner JPMP GLOBAL INVESTORS L P · CIK 0001281161 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 168,950 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: The Series B and Series C Convertible Preferred Stock is immediately exercisable. It has no expiration date. Upon the close of the Issuer's initial public offering, these shares were automatically converted into Common Stock of the Issuer. These shares are convertible on a two for one basis. F5 · derivative.expiration_date: The Series B and Series C Convertible Preferred Stock is immediately exercisable. It has no expiration date. Upon the close of the Issuer's initial public offering, these shares were automatically converted into Common Stock of the Issuer. These shares are convertible on a two for one basis. F2 · ownership.nature: The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors (Cayman), L.P. Read SEC document
April 28, 2004 Filed Apr 30, 2004 18:52 UTC	BARRIER THERAPEUTICS INC BTRX · Entity 13927	ConversionSeries B Convertible Preferred Stock · Derivative	665,744	$0.00	$0.00	Disclosure SEC source: 0001125282-04-001878 · b331679_ex.xml · derivative · entry 7 JP MORGAN PARTNERS BHCA LP · CIK 0001106607 · 10% owner JPMP MASTER FUND MANAGER L P · CIK 0001243235 · 10% owner JPMP CAPITAL CORP · CIK 0001243236 · 10% owner J P MORGAN CHASE & CO · CIK 0000019617 · 10% owner JP MORGAN PARTNERS GLOBAL INVESTORS LP · CIK 0001162622 · 10% owner J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN LP · CIK 0001169890 · 10% owner J P MORGAN PARTNERS GLOBAL INVESTORS A LP · CIK 0001167095 · 10% owner J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN II LP · CIK 0001169889 · 10% owner JPMP GLOBAL INVESTORS L P · CIK 0001281161 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 332,872 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: The Series B and Series C Convertible Preferred Stock is immediately exercisable. It has no expiration date. Upon the close of the Issuer's initial public offering, these shares were automatically converted into Common Stock of the Issuer. These shares are convertible on a two for one basis. F5 · derivative.expiration_date: The Series B and Series C Convertible Preferred Stock is immediately exercisable. It has no expiration date. Upon the close of the Issuer's initial public offering, these shares were automatically converted into Common Stock of the Issuer. These shares are convertible on a two for one basis. F1 · ownership.nature: The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors, L.P. Read SEC document
April 28, 2004 Filed Apr 30, 2004 18:52 UTC	BARRIER THERAPEUTICS INC BTRX · Entity 13927	ConversionSeries B Convertible Preferred Stock · Derivative	4,201,280	$0.00	$0.00	Disclosure SEC source: 0001125282-04-001878 · b331679_ex.xml · derivative · entry 6 JP MORGAN PARTNERS BHCA LP · CIK 0001106607 · 10% owner JPMP MASTER FUND MANAGER L P · CIK 0001243235 · 10% owner JPMP CAPITAL CORP · CIK 0001243236 · 10% owner J P MORGAN CHASE & CO · CIK 0000019617 · 10% owner JP MORGAN PARTNERS GLOBAL INVESTORS LP · CIK 0001162622 · 10% owner J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN LP · CIK 0001169890 · 10% owner J P MORGAN PARTNERS GLOBAL INVESTORS A LP · CIK 0001167095 · 10% owner J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN II LP · CIK 0001169889 · 10% owner JPMP GLOBAL INVESTORS L P · CIK 0001281161 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,100,640 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: The Series B and Series C Convertible Preferred Stock is immediately exercisable. It has no expiration date. Upon the close of the Issuer's initial public offering, these shares were automatically converted into Common Stock of the Issuer. These shares are convertible on a two for one basis. F5 · derivative.expiration_date: The Series B and Series C Convertible Preferred Stock is immediately exercisable. It has no expiration date. Upon the close of the Issuer's initial public offering, these shares were automatically converted into Common Stock of the Issuer. These shares are convertible on a two for one basis. Read SEC document
April 28, 2004 Filed Apr 30, 2004 18:52 UTC	BARRIER THERAPEUTICS INC BTRX · Entity 13927	ConversionCommon Stock	22,483	$0.00	$0.00	Disclosure SEC source: 0001125282-04-001878 · b331679_ex.xml · nonDerivative · entry 5 JP MORGAN PARTNERS BHCA LP · CIK 0001106607 · 10% owner JPMP MASTER FUND MANAGER L P · CIK 0001243235 · 10% owner JPMP CAPITAL CORP · CIK 0001243236 · 10% owner J P MORGAN CHASE & CO · CIK 0000019617 · 10% owner JP MORGAN PARTNERS GLOBAL INVESTORS LP · CIK 0001162622 · 10% owner J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN LP · CIK 0001169890 · 10% owner J P MORGAN PARTNERS GLOBAL INVESTORS A LP · CIK 0001167095 · 10% owner J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN II LP · CIK 0001169889 · 10% owner JPMP GLOBAL INVESTORS L P · CIK 0001281161 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 22,483 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · ownership.nature: The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors (Cayman) II, L.P. Read SEC document
April 28, 2004 Filed Apr 30, 2004 18:52 UTC	BARRIER THERAPEUTICS INC BTRX · Entity 13927	ConversionCommon Stock	55,380	$0.00	$0.00	Disclosure SEC source: 0001125282-04-001878 · b331679_ex.xml · nonDerivative · entry 4 JP MORGAN PARTNERS BHCA LP · CIK 0001106607 · 10% owner JPMP MASTER FUND MANAGER L P · CIK 0001243235 · 10% owner JPMP CAPITAL CORP · CIK 0001243236 · 10% owner J P MORGAN CHASE & CO · CIK 0000019617 · 10% owner JP MORGAN PARTNERS GLOBAL INVESTORS LP · CIK 0001162622 · 10% owner J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN LP · CIK 0001169890 · 10% owner J P MORGAN PARTNERS GLOBAL INVESTORS A LP · CIK 0001167095 · 10% owner J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN II LP · CIK 0001169889 · 10% owner JPMP GLOBAL INVESTORS L P · CIK 0001281161 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 55,380 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · ownership.nature: The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors A, L.P. Read SEC document
April 28, 2004 Filed Apr 30, 2004 18:52 UTC	BARRIER THERAPEUTICS INC BTRX · Entity 13927	ConversionCommon Stock	201,635	$0.00	$0.00	Disclosure SEC source: 0001125282-04-001878 · b331679_ex.xml · nonDerivative · entry 3 JP MORGAN PARTNERS BHCA LP · CIK 0001106607 · 10% owner JPMP MASTER FUND MANAGER L P · CIK 0001243235 · 10% owner JPMP CAPITAL CORP · CIK 0001243236 · 10% owner J P MORGAN CHASE & CO · CIK 0000019617 · 10% owner JP MORGAN PARTNERS GLOBAL INVESTORS LP · CIK 0001162622 · 10% owner J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN LP · CIK 0001169890 · 10% owner J P MORGAN PARTNERS GLOBAL INVESTORS A LP · CIK 0001167095 · 10% owner J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN II LP · CIK 0001169889 · 10% owner JPMP GLOBAL INVESTORS L P · CIK 0001281161 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 201,635 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · ownership.nature: The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors (Cayman), L.P. Read SEC document
April 28, 2004 Filed Apr 30, 2004 18:52 UTC	BARRIER THERAPEUTICS INC BTRX · Entity 13927	ConversionCommon Stock	397,975	$0.00	$0.00	Disclosure SEC source: 0001125282-04-001878 · b331679_ex.xml · nonDerivative · entry 2 JP MORGAN PARTNERS BHCA LP · CIK 0001106607 · 10% owner JPMP MASTER FUND MANAGER L P · CIK 0001243235 · 10% owner JPMP CAPITAL CORP · CIK 0001243236 · 10% owner J P MORGAN CHASE & CO · CIK 0000019617 · 10% owner JP MORGAN PARTNERS GLOBAL INVESTORS LP · CIK 0001162622 · 10% owner J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN LP · CIK 0001169890 · 10% owner J P MORGAN PARTNERS GLOBAL INVESTORS A LP · CIK 0001167095 · 10% owner J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN II LP · CIK 0001169889 · 10% owner JPMP GLOBAL INVESTORS L P · CIK 0001281161 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 397,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors, L.P. Read SEC document
April 28, 2004 Filed Apr 30, 2004 18:52 UTC	BARRIER THERAPEUTICS INC BTRX · Entity 13927	ConversionCommon Stock	2,470,800	$0.00	$0.00	Disclosure SEC source: 0001125282-04-001878 · b331679_ex.xml · nonDerivative · entry 1 JP MORGAN PARTNERS BHCA LP · CIK 0001106607 · 10% owner JPMP MASTER FUND MANAGER L P · CIK 0001243235 · 10% owner JPMP CAPITAL CORP · CIK 0001243236 · 10% owner J P MORGAN CHASE & CO · CIK 0000019617 · 10% owner JP MORGAN PARTNERS GLOBAL INVESTORS LP · CIK 0001162622 · 10% owner J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN LP · CIK 0001169890 · 10% owner J P MORGAN PARTNERS GLOBAL INVESTORS A LP · CIK 0001167095 · 10% owner J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN II LP · CIK 0001169889 · 10% owner JPMP GLOBAL INVESTORS L P · CIK 0001281161 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,470,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.